Hou, Lei https://orcid.org/0000-0003-0540-2706
Li, Yue https://orcid.org/0000-0003-3844-4865
Xiong, Xushen https://orcid.org/0000-0001-7090-7503
Tanigawa, Yosuke https://orcid.org/0000-0001-9759-157X
Park, Yongjin https://orcid.org/0000-0001-8915-2876
Lenz, Samuel W.
Grayson, Amy
Lee, Jeong-Heon https://orcid.org/0000-0003-4007-9166
Ryu, Euijung
Olson, Janet E. https://orcid.org/0000-0003-4944-7789
Biernacka, Joanna M. https://orcid.org/0000-0001-9350-4440
Frye, Mark A. https://orcid.org/0000-0001-6997-4215
Ordog, Tamas https://orcid.org/0000-0002-3940-7284
Kellis, Manolis https://orcid.org/0000-0001-7113-9630
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK126827)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK084567)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK057061)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG058002)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH109978)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH119509)
Article History
Received: 10 July 2025
Accepted: 20 April 2026
First Online: 15 May 2026
Competing interests
: Mark A. Frye M.D. has received research support from Assurex Health, Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2), Baszucki Brain Group, and Mayo Foundation; received CME Travel and Honoraria from Carnot Laboratories and has Financial Interest/Stock ownership/Royalties with Chymia LLC. The remaining authors declare no competing interests.